170 related articles for article (PubMed ID: 28410213)
1. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.
Cui M; Gao XS; Gu X; Guo W; Li X; Ma M; Qin S; Qi X; Xie M; Peng C; Bai Y
Oncotarget; 2017 Jun; 8(25):40222-40232. PubMed ID: 28410213
[TBL] [Abstract][Full Text] [Related]
2. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
4. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
[TBL] [Abstract][Full Text] [Related]
5. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
Thorne H; Willems AJ; Niedermayr E; Hoh IM; Li J; Clouston D; Mitchell G; Fox S; Hopper JL; ; Bolton D
Cancer Prev Res (Phila); 2011 Jul; 4(7):1002-10. PubMed ID: 21733824
[TBL] [Abstract][Full Text] [Related]
6. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
[TBL] [Abstract][Full Text] [Related]
7. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
8. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.
Akbari MR; Wallis CJ; Toi A; Trachtenberg J; Sun P; Narod SA; Nam RK
Br J Cancer; 2014 Sep; 111(6):1238-40. PubMed ID: 25101567
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer progression and survival in BRCA2 mutation carriers.
Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
[TBL] [Abstract][Full Text] [Related]
10. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
[TBL] [Abstract][Full Text] [Related]
11. Altered significance of D'Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort.
Bolton D; Cheng Y; Willems-Jones AJ; Li J; Niedermeyr E; Mitchell G; Clouston D; Lawrentschuk N; Sliwinski A; Fox S; Thorne H
BJU Int; 2015 Aug; 116(2):207-12. PubMed ID: 24784491
[TBL] [Abstract][Full Text] [Related]
12. Effect of BRCA2 mutation on familial breast cancer survival: A systematic review and meta-analysis.
Shao J; Yang J; Wang JN; Qiao L; Fan W; Gao QL; Feng YJ
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):629-634. PubMed ID: 26489613
[TBL] [Abstract][Full Text] [Related]
13. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
Tryggvadottir L; Olafsdottir EJ; Olafsdottir GH; Sigurdsson H; Johannsson OT; Bjorgvinsson E; Alexiusdottir K; Stefansson OA; Agnarsson BA; Narod SA; Eyfjord JE; Jonasson JG
Breast Cancer Res Treat; 2013 Jul; 140(2):375-84. PubMed ID: 23857704
[TBL] [Abstract][Full Text] [Related]
14. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
[TBL] [Abstract][Full Text] [Related]
15. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer in a man with a BRCA2 mutation and a personal history of bilateral breast cancer.
Singer CF; Rappaport-Fuerhauser C; Sopik V; Narod SA
Clin Genet; 2015 Aug; 88(2):187-9. PubMed ID: 25112434
[TBL] [Abstract][Full Text] [Related]
17. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
[TBL] [Abstract][Full Text] [Related]
18. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
Lozano R; Salles DC; Sandhu S; Aragón IM; Thorne H; López-Campos F; Rubio-Briones J; Gutierrez-Pecharroman AM; Maldonado L; di Domenico T; Sanz A; Prieto JD; García I; Pacheco MI; Garcés T; Llacer C; Romero-Laorden N; Zambrana F; López-Casas PP; Lorente D; Mateo J; Pritchard CC; Antonarakis ES; Olmos D; Lotan TL; Castro E
Eur J Cancer; 2021 Apr; 147():74-83. PubMed ID: 33626496
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
Roed Nielsen H; Petersen J; Therkildsen C; Skytte AB; Nilbert M
Acta Oncol; 2016; 55(1):38-44. PubMed ID: 26360800
[TBL] [Abstract][Full Text] [Related]
20. Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.
Gleicher S; Kauffman EC; Kotula L; Bratslavsky G; Vourganti S
Prostate; 2016 Sep; 76(13):1135-45. PubMed ID: 27225637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
